166 related articles for article (PubMed ID: 26827760)
1. Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.
Taylor NJ; Handorf EA; Mitra N; Avril MF; Azizi E; Bergman W; Bianchi-Scarrà G; Bishop DT; Bressac-de Paillerets B; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Friedman E; Gerdes AM; Ghiorzo P; Goldstein AM; Grazziotin TC; Hansson J; Hayward NK; Hocevar M; Höiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer J; Perić B; Pjanova D; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Whitaker L; Yang XR; Newton Bishop JA; Gruis NA; Kanetsky PA;
J Invest Dermatol; 2016 May; 136(5):1066-1069. PubMed ID: 26827760
[No Abstract] [Full Text] [Related]
2. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A.
van der Rhee JI; Krijnen P; Gruis NA; de Snoo FA; Vasen HFA; Putter H; Kukutsch NA; Bergman W
J Am Acad Dermatol; 2011 Aug; 65(2):281-288. PubMed ID: 21570156
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of Familial Melanoma in Valencia, Spain, Based on the Presence of CDKN2A Mutations and MC1R Variants.
Huerta C; Garcia-Casado Z; Bañuls J; Moragon M; Oliver V; Unamuno B; Requena C; Kumar R; Nagore E
Acta Derm Venereol; 2018 Apr; 98(5):512-516. PubMed ID: 29405243
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.
Karagianni F; Njauw CN; Kypreou KP; Stergiopoulou A; Plaka M; Polydorou D; Chasapi V; Pappas L; Stratigos IA; Champsas G; Panagiotou P; Gogas H; Evangelou E; Tsao H; Stratigos AJ; Stefanaki I
Acta Derm Venereol; 2018 Oct; 98(9):862-866. PubMed ID: 29774366
[TBL] [Abstract][Full Text] [Related]
5. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
Betti M; Aspesi A; Biasi A; Casalone E; Ferrante D; Ogliara P; Gironi LC; Giorgione R; Farinelli P; Grosso F; Libener R; Rosato S; Turchetti D; Maffè A; Casadio C; Ascoli V; Dianzani C; Colombo E; Piccolini E; Pavesi M; Miccoli S; Mirabelli D; Bracco C; Righi L; Boldorini R; Papotti M; Matullo G; Magnani C; Pasini B; Dianzani I
Cancer Lett; 2016 Aug; 378(2):120-30. PubMed ID: 27181379
[TBL] [Abstract][Full Text] [Related]
6. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
[TBL] [Abstract][Full Text] [Related]
7. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
Mangas C; Potrony M; Mainetti C; Bianchi E; Carrozza Merlani P; Mancarella Eberhardt A; Maspoli-Postizzi E; Marazza G; Marcollo-Pini A; Pelloni F; Sessa C; Simona B; Puig-Butillé JA; Badenas C; Puig S
Br J Dermatol; 2016 Nov; 175(5):1030-1037. PubMed ID: 27473757
[TBL] [Abstract][Full Text] [Related]
8. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations.
Helgadottir H; Olsson H; Tucker MA; Yang XR; Höiom V; Goldstein AM
Genet Med; 2018 Sep; 20(9):1087-1090. PubMed ID: 29215650
[TBL] [Abstract][Full Text] [Related]
9. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
[TBL] [Abstract][Full Text] [Related]
10. [CDKN2A-mutation in a family with hereditary malignant melanoma].
Djursby M; Wadt K; Lorentzen H; Borg A; Gerdes AM; Krogh L
Ugeskr Laeger; 2014 Sep; 176(40):. PubMed ID: 25294512
[TBL] [Abstract][Full Text] [Related]
11. Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.
Taylor NJ; Mitra N; Goldstein AM; Tucker MA; Avril MF; Azizi E; Bergman W; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Gerdes AM; Ghiorzo P; Grazziotin TC; Hansson J; Harland M; Hayward NK; Hocevar M; Höiom V; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer JM; Perić B; Pjanova D; Pritchard A; Puig S; van der Stoep N; Wadt KAW; Whitaker L; Yang XR; Newton Bishop JA; Gruis NA; Kanetsky PA;
J Invest Dermatol; 2017 Dec; 137(12):2606-2612. PubMed ID: 28830827
[TBL] [Abstract][Full Text] [Related]
12. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions.
Harms PW; Hocker TL; Zhao L; Chan MP; Andea AA; Wang M; Harms KL; Wang ML; Carskadon S; Palanisamy N; Fullen DR
Hum Pathol; 2016 Dec; 58():152-160. PubMed ID: 27569296
[TBL] [Abstract][Full Text] [Related]
13. Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree.
Florell SR; Meyer LJ; Boucher KM; Grossman D; Cannon-Albright LA; Harris RM; Samlowski WE; Zone JJ; Leachman SA
J Invest Dermatol; 2008 Aug; 128(8):2122-5. PubMed ID: 18337833
[No Abstract] [Full Text] [Related]
14. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.
Levin T; Mæhle L
Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060
[TBL] [Abstract][Full Text] [Related]
15. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.
Delaunay J; Martin L; Bressac-de Paillerets B; Duru G; Ingster O; Thomas L
JAMA Dermatol; 2017 Nov; 153(11):1122-1129. PubMed ID: 28903138
[TBL] [Abstract][Full Text] [Related]
16. CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
De Unamuno B; García-Casado Z; Bañuls J; Requena C; Lopez-Guerrero JA; Nagore E
Melanoma Res; 2018 Jun; 28(3):246-249. PubMed ID: 29543703
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
[TBL] [Abstract][Full Text] [Related]
18. Pediatric melanoma in melanoma-prone families.
Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
[TBL] [Abstract][Full Text] [Related]
19. Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma.
Puig S; Potrony M; Cuellar F; Puig-Butille JA; Carrera C; Aguilera P; Nagore E; Garcia-Casado Z; Requena C; Kumar R; Landman G; Costa Soares de Sá B; Gargantini Rezze G; Facure L; de Avila AL; Achatz MI; Carraro DM; Duprat Neto JP; Grazziotin TC; Bonamigo RR; Rey MC; Balestrini C; Morales E; Molgo M; Bakos RM; Ashton-Prolla P; Giugliani R; Larre Borges A; Barquet V; Pérez J; Martínez M; Cabo H; Cohen Sabban E; Latorre C; Carlos-Ortega B; Salas-Alanis JC; Gonzalez R; Olazaran Z; Malvehy J; Badenas C
Genet Med; 2016 Jul; 18(7):727-36. PubMed ID: 26681309
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature.
Sargen MR; Merrill SL; Chu EY; Nathanson KL
Br J Dermatol; 2016 Oct; 175(4):785-9. PubMed ID: 26876133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
